{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T19:35:37Z","timestamp":1768678537344,"version":"3.49.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,24]]},"DOI":"10.7759\/cureus.28330","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T07:45:33Z","timestamp":1661327133000},"source":"Crossref","is-referenced-by-count":3,"title":["A Challenging Case of Eyelid Ptosis and Diplopia Induced by Pembrolizumab"],"prefix":"10.7759","author":[{"given":"Daniela","family":"Garcez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Isabel","family":"Clara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Francisca","family":"Moraes-Fontes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Bravo","family":"Marques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418799864","article-title":"Neurological complications of immune checkpoint inhibitors: what happens when you 'take the brakes off' the immune system","volume":"11","author":"Dalakas MC","year":"2018","unstructured":"Dalakas MC. Neurological complications of immune checkpoint inhibitors: what happens when you 'take the brakes off' the immune system. Ther Adv Neurol Disord. 2018, 11:10.1177\/1756286418799864","journal-title":"Ther Adv Neurol Disord"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102189","article-title":"Neurological complications of cancer immunotherapy","volume":"97","author":"Roth P","year":"2021","unstructured":"Roth P, Winklhofer S, M\u00fcller AM, et al.. Neurological complications of cancer immunotherapy. Cancer Treat Rev. 2021, 97:10.1016\/j.ctrv.2021.102189","journal-title":"Cancer Treat Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-019-1416-1","article-title":"Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report","volume":"19","author":"Kamo H","year":"2019","unstructured":"Kamo H, Hatano T, Kanai K, et al.. Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report. BMC Neurol. 2019, 19:10.1186\/s12883-019-1416-1","journal-title":"BMC Neurol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2020.02.013","article-title":"Immune checkpoint inhibitors (ICIs)-related ocular myositis","volume":"30","author":"Garibaldi M","year":"2020","unstructured":"Garibaldi M, Calabr\u00f2 F, Merlonghi G, et al.. Immune checkpoint inhibitors (ICIs)-related ocular myositis. Neuromuscul Disord. 2020, 30:420-3. 10.1016\/j.nmd.2020.02.013","journal-title":"Neuromuscul Disord"},{"key":"ref5","unstructured":"e-Pearl of the week. Cogan\u2019s lid twitch sign. (2020). Accessed: July 1, 2022: https:\/\/n.neurology.org\/epearls\/20200831."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2007.02.020","article-title":"A prospective study assessing the utility of Cogan's lid twitch sign in patients with isolated unilateral or bilateral ptosis","volume":"256","author":"Van Stavern GP","year":"2007","unstructured":"Van Stavern GP, Bhatt A, Haviland J, Black EH. A prospective study assessing the utility of Cogan's lid twitch sign in patients with isolated unilateral or bilateral ptosis. J Neurol Sci. 2007, 256:84-5. 10.1016\/j.jns.2007.02.020","journal-title":"J Neurol Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13931","article-title":"Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases","volume":"26","author":"Pathak R","year":"2021","unstructured":"Pathak R, Katel A, Massarelli E, Villaflor VM, Sun V, Salgia R. Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases. Oncologist. 2021, 26:1052-61. 10.1002\/onco.13931","journal-title":"Oncologist"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider B","year":"2021","unstructured":"Schneider B, Naidoo J, Santomasso B, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021, 39:4073-126. 10.1200\/jco.21.01440","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa H","year":"2019","unstructured":"Safa H, Johnson DH, Trinh VA, et al.. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019, 7:10.1186\/s40425-019-0774-y","journal-title":"J Immunother Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille C","year":"2020","unstructured":"Dolladille C, Ederhy S, Sassier M, et al.. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol. 2020, 6:865-71. 10.1001\/jamaoncol.2020.0726","journal-title":"JAMA Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.730320","article-title":"Safety and efficacy of the rechallenge of immune checkpoint inhibitors after immune-related adverse events in patients with cancer: a systemic review and Meta-analysis","volume":"12","author":"Zhao Q","year":"2021","unstructured":"Zhao Q, Zhang J, Xu L, et al.. Safety and efficacy of the rechallenge of immune checkpoint inhibitors after immune-related adverse events in patients with cancer: a systemic review and Meta-analysis. Front Immunol. 2021, 12:10.3389\/fimmu.2021.730320","journal-title":"Front Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/106607-a-challenging-case-of-eyelid-ptosis-and-diplopia-induced-by-pembrolizumab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:48:21Z","timestamp":1707508101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/106607-a-challenging-case-of-eyelid-ptosis-and-diplopia-induced-by-pembrolizumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,24]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.28330","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,24]]}}}